An Evaluation of the Ability to Train Established Glaucoma Patients Who Have Difficulty in Drop Instillation
NCT ID: NCT01719809
Last Updated: 2017-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
18 participants
OBSERVATIONAL
2012-10-31
2015-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A patient will be identified as properly instilling a drop if they satisfy the following criteia:
They are able to instill one (and only one) drop to the ocular surface or lower fornix without allowing the bottle touch the adnexa, eyelid, eye lashes or eye.
All patients routinely return between 3 and 6 months. At this regularly scheduled visit,the investigator or trained personnel would direct the patient to instill an eye drop into the study eye.Additionally, the short glaucoma self-efficacy questionnaire will be re-administered.
All of the video-recordings of participants' eye drop instillation techniques will be reviewed and assessed using a standard checklist. Their ability to administer an eye drop after training will be compared to baseline.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance
NCT00329095
Observational Study of How Patients Take Eye Drops
NCT00750646
Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients
NCT00069719
Anecortave Acetate in Patients With Open-angle Glaucoma
NCT00320203
iDropper Usability in Glaucoma
NCT02031380
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients currently using topical ocular antihypertensive medications at the time of enrollment in at least one eye, and who have been using these drops consistently for a period of at least three months prior to enrollment.
* Patients with primary open angle glaucoma, pigmentary glaucoma, exfoliation glaucoma, ocular hypertension, normal-tension glaucoma, neovascular glaucoma, uveitic glaucoma and chronic narrow angle glaucoma.
* Patients CAN be enrolled even if they have co-existing morbidities such as Parkinson's Disease or arthritis
Exclusion Criteria
* Patients who are not expected to still be using topical antihypertensive medications at the time of study follow-up
* Patients with no light perception vision
* Patients with a history of adverse reaction to artificial tears or any component of artificial tears
* Patients who have a typical follow-up period of greater than 6 months
* Patients who have not completed a Humphrey Visual Field C24-2 or C10-2 within 7 months of enrollment or study exit.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Robin, Alan L., M.D.
INDIV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adam C. LePosa
Adam C. LePosa, O.D
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adam C LePosa, OD
Role: PRINCIPAL_INVESTIGATOR
Alan L. Robin, MD, PA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alan L. Robin, MD, PA
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALR 0054
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.